Early stage molecular diagnostics company NuProbe has announced the closing of a $11 million Series A round of funding led by Sequoia Capital China and Serica Partners to continue its development of ultra-sensitive, non-invasive blood test for the early detection of cancer and infectious diseases. Boston - based company has closed an $ 80 million series A funding round , led by Sequoia Capital China and Serica Partners . Molecular diagnostic specialist NuProbe has developed a highly sensitive , non - invasive blood test enabling the early detection of cancer and other diseases . The latest technology will be used to continue clinical trials and for work on developing a commercial product , as well as to expand staffing at NuProbe 's US and UK offices . Private US biotechnology firms received $ 1.4bn of Chinese investment during Q1 2018 , according to Forbes .
Boston - based company has closed an $ 80 million series A funding round , led by Sequoia Capital China and Serica Partners . Molecular diagnostic specialist NuProbe has developed a highly sensitive , non - invasive blood test enabling the early detection of cancer and other diseases . The latest technology will be used to continue clinical trials and for work on developing a commercial product , as well as to expand staffing at NuProbe 's US and UK offices . Private US biotechnology firms received $ 1.4bn of Chinese investment during Q1 2018 , according to Forbes .